Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy

Shahid Beheshti University of Medical Sciences

Overview

Purpose: There are some controversies about the effect of Levodopa-Carbidopa on treatment of non-arteritic anterior ischemic optic neuropathy (NAION). This study was performed to evaluate the effect of Levodopa-Carbidopa on visual acuity, color vision, and visual field in patients with recent onset NAION (less than 6 weeks duration). Patients and Methods: In this double-blind randomized clinical trial, 13 patients were treated with levodopa-carbidopa and 12 patients took placebo for 3 weeks. Visual acuity, color vision, and visual field were tested before and at 4th, 12th, 16th, and 24th weeks after enrollment, and evaluated.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Nonarteritic Anterior Ischemic Optic Neuropathy

Interventions

levodopa-carbidopaDRUG

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age greater than 50 years old * first ophthalmic examination within 6 weeks after onset of disease * presence of optic disc swelling followed by optic atrophy within 6 weeks * altitudinal, central or generalized visual field defect * normal ESR Exclusion Criteria: * confirmed giant cell arteritis * history of any ocular surgeries * optic neuropathy due to acute bleeding * advanced diabetic retinopathy * uncontrolled glaucoma * any ocular disorders that cause visual acuity reduction rather than NAION

Locations (1)

Ophthalmic research center

Tehran, Tehran Province, Iran

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.